TEP/TDM en radiothérapie :

indications et perspectives

Lucia F (1, 2, 3), Withofs N (3, 4), Lovinfosse P (3, 4), Hustinx R (3, 4)

Bibliographie

1. Grégoire V, Haustermans K, Geets X,et al. PET-based treatment planning in radiotherapy: a new standard? *J Nucl Med* 2007;**48** (Suppl1):68S-77S.

2. Isnardi V, Thureau S, Vera P. Impact of positron emission tomography with computed tomography for image-guided radiotherapy. *Cancer Radiother* 2020;**24**:362-7.

3. Zimmerman ME, Meyer AR, Rowe SP, Gorin MA. Imaging of prostate cancer with positron emission tomography. *Clin Adv Hematol Oncol* 2019;**17**:455-63.

4. Pinker K, Andrzejewski P, Baltzer P, et al. Multiparametric [18F]fluorodeoxyglucose/ [18F]fluoromisonidazole positron emission tomography/ magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: a pilot study. *PLoS One* 2016;**11**:e0155333.

5. Kauczor H-U, Zechmann C, Stieltjes B, Weber M-A. Functional magnetic resonance imaging for defining the biological target volume. *Cancer Imaging* 2006;**6**:51-5.

6. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 2012;**48**:441-6.

7. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol* 2017;**14**:749-62.

8. Roberts HJ, Zietman AL, Efstathiou JA. Painting dose: the art of radiation. *Int J Radiat Oncol Biol Phys* 2016;**96**:722-8.

9. Xiao J, Jin Y, Nie J, et al. Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. *BMC Cancer* 2019;**19**:767.

10. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoroethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. *J Nucl Med* 2012;**53**:207-14.

11. Unterrainer M, Galldiks N, Suchorska B, et al. 18F-FET PET uptake characteristics in patients with newly diagnosed and untreated brain metastasis. *J Nucl Med* 2017;**58**:584-9.

12. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. *Neuro Oncol* 2011;**13**:307-16.

13. Lohmann P, Werner J-M, Shah NJ, et al. Combined amino acid positron emission tomography and advanced magnetic resonance imaging in glioma patients. *Cancers (Basel)* 2019;**11**:153.

14. Verburg N, Hoefnagels FW, Barkhof F, et al. Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis. *AJNR Am J Neuroradiol* 2017;**38**:1884-91.

15. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;**63**:511-9.

16. Laack NN, Pafundi D, Anderson SK, et al. Initial results of a phase 2 trial of 18F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma. *Int J Radiat Oncol Biol Phys* 2021;**110**:1383-95.

17. Schlürmann T, Waschulzik B, Combs S, et al. Utility of amino acid pet in the differential diagnosis of recurrent brain metastases and treatment-related changes: a meta-analysis. *J Nucl Med* 2023;**64**:816-21.

18. Karunanithi S, Sharma P, Kumar A, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. *Eur J Nucl Med Mol Imaging* 2013;**40**:1025-35.

19. Herrmann K, Czernin J, Cloughesy T , et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. *Neuro Oncol* 2014;**16**:603-9.

20. Farce J, Lecouillard I, Carsin Nicol B, et al. Intracavernous Schwannoma characterized With 18F-FDG, 68Ga-DOTATOC, and 18F-choline PET. *Clin Nucl Med* 2022;**47**:e165-6.

21. Afshar-Oromieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. *Eur J Nucl Med Mol Imaging* 2012;**39**:1409-15.

22. Graf R, Nyuyki F, Steffen IG, et al. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;**85**:68-73.

23. Allard B, Dissaux B, Bourhis D, et al. Hotspot on 18F-FET PET/CT to predict aggressive tumor areas for radiotherapy dose escalation guiding in high-grade glioma. *Cancers (Basel)* 2022;**15**:98.

24. Oehlke O, Mix M, Graf E, et al. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). *BMC Cancer* 2016;**16**:769.

25. Mehanna H, Wong W-L, McConkey CC, et al. PET-CT Surveillance versus neck dissection in advanced head and neck cancer. *N Engl J Med* 2016;**374**:1444-54.

26. Wong WL. PET-CT for staging and detection of recurrence of head and neck cancer. *Semin Nucl Med* 2021;**51**:13-25.

27. Helsen N, Roothans D, Van Den Heuvel B, et al. 18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. *PLoS One* 2017;**12**:e0182350.

28. Yamamoto Y, Wong TZ, Turkington TG, et al. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. *Radiology* 2007;**244**:263-72.

29. Rodrigues RS, Bozza FA, Christian PE, et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. *J Nucl Med* 2009;**50**:1205-13.

30. Chen T-M, Chen W-M, Chen M, et al. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning. *J Otolaryngol Head Neck Surg* 2023;**52**:14.

31. Marcus C, Ciarallo A, Tahari AK, et al. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. *J Nucl Med* 2014;**55**:1411-6.

32. Cacicedo J, Navarro A, Del Hoyo O, et al. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. *Br J Radiol* 2016;**89**:20160217.

33. Arunsingh M, Vaidyanathan S, Dyker KE, et al. Accuracy of response assessment positron emission tomography-computed tomography following definitive radiotherapy without chemotherapy for head and neck squamous cell carcinoma. *Clin Oncol (R Coll Radiol)* 2019;**31**:212-8.

34. Adjogatse D, Michaelidou A, Sanchez Nieto B, et al. Protocol letter: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study (InGReS) - A Phase 1 multicentre feasibility study. *Radiother Oncol* 2023;**183**:109645.

35. van den Bosch S, Dijkema T, Kunze-Busch MC, et al. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. *BMC Cancer* 2017;**17**:208.

36. Torres-Roca JF. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. *Per Med* 2012;**9**:547-57.

37. Overgaard J, Horsman MR. Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. *Semin Radiat Oncol* 1996;**6**:10-21.

38. Wang J-S, Wang H-J, Qian H-L. Biological effects of radiation on cancer cells. *Mil Med Res* 2018;**5**:20.

39. Bredell MG, Ernst J, El-Kochairi I, et al. Current relevance of hypoxia in head and neck cancer. *Oncotarget* 2016;**7**: 50781-804.

40. Rühle A, Grosu A-L, Wiedenmann N, et al. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with head-and-neck squamous cell carcinoma undergoing chemoradiation. *Theranostics* 2020;**10**:9395-406.

41. Löck S, Perrin R, Seidlitz A, et al. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. *Radiother Oncol* 2017;**124**:533-40.

42. Mortensen LS, Johansen J, Kallehauge J, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. *Radiother Oncol* 2012;**105**:14-20.

43. Troost EGC, Laverman P, Philippens MEP , et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. *Eur J Nucl Med Mol Imaging* 2008;**35**:1803-11.

44. Zips D, Zöphel K, Abolmaali N, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. *Radiother Oncol* 2012;**105**:21-8.

45. Grosu A-L, Souvatzoglou M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2007;**69**:541-51.

46. Wiedenmann N, Grosu A-L, Büchert M, et al. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. *Radiother Oncol* 2020;**150**:128–35.

47. Nicolay NH, Wiedenmann N, Mix M, et al. Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial. *Eur J Nucl Med Mol Imaging* 2020;**47**:1046-55.

48. Riaz N, Sherman E, Pei X , et al. Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. *J Natl Cancer Inst* 2021;**113**:742-51.

49. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. *J Nucl Med* 2007;**48**:726-35.

50. Hoeben BA, Troost EG, Span PN, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. *J Nucl Med* 2013;**54**:532-40.

51. Troost EG, Bussink J, Hoffmann AL, et al 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. *J Nucl Med* 2010;**51**:866-74.

52. Syed M, Flechsig P, Liermann J, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. *Eur J Nucl Med Mol Imaging* 2020;**47**:2836-45.

53. Ajani JA, Barthel JS, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers. *J Natl Compr Canc Netw* 2011;**9**:830-87.

54. Vaz SC, Adam JA, Delgado Bolton RC, et al. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. *Eur J Nucl Med Mol Imaging* 2022;**49**:1386-406.

55. Kandathil A, Subramaniam RM. FDG PET/CT for primary staging of lung cancer and mesothelioma. *Semin Nucl Med* 2022;**52**:650-61.

56. Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in different types of lung cancer: an overview. *Eur J Radiol* 2012;**81**:988-1001.

57. Manapov F, Eze C, Holzgreve A, et al. PET/CT for target delineation of lung cancer before radiation therapy. *Semin Nucl Med* 2022;**52**:673-80.

58. Sterbis E, Liang R, Trivedi P, et al. Lack of adherence to guideline-based imaging before subsequent radiation in patients with non-small cell lung cancer: impact on patient outcomes. *J Nucl Med* 2023;**64**:75-81.

59. Nakajima N, Sugawara Y, Kataoka M,, et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. *Ann Nucl Med* 2013;**27**:261-70.

60. Lodge MA. Repeatability of SUV in oncologic 18F-FDG PET. *J Nucl Med* 2017;**58**:523-32.

61. Bollineni VR, Koole MJB, Pruim J, et al. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. *Radiother Oncol* 2014;**113**:198-203.

62. Bollineni VR, Kerner GSMA, Pruim J, et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. *J Nucl Med* 2013;**54**:1175-80.

63. Everitt SJ, Ball DL, Hicks RJ, et al. Differential (18)F-FDG and (18)F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. *J Nucl Med* 2014;**55**:1069-74.

64. Everitt S, Ball D, Hicks RJ, et al. Prospective study of serial imaging comparing fluorodeoxyglucose positron emission tomography (PET) and fluorothymidine PET during radical chemoradiation for non-small cell lung cancer: reduction of detectable proliferation associated with worse survival. *Int J Radiat Oncol Biol Phys* 2017;**99**:947-55.

65. Wei Y, Zheng J, Ma L, et al. [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. *Eur J Nucl Med Mol Imaging* 2022;**49**:2761-73.

66. Gates ED, Hippe DS, Vesselle HJ,et al. Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response? *Radiother Oncol* 2023;**185**:109720.

67. Bucknell NW, Hardcastle N, Woon B, et al. The HI-FIVE Trial: A prospective trial using 4-dimensional 68Ga ventilation-perfusion positron emission tomography-computed tomography for functional lung avoidance in locally advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2023;**117**:887-92.

68. Lucia F, Rehn M, Blanc-Béguin F, Le Roux P-Y. Radiation therapy planning of thoracic tumors: a review of challenges associated with lung toxicities and potential perspectives of Gallium-68 lung PET/CT imaging. *Front Med (Lausanne)* 2021;**8**:723748.

69. Pinot F, Bourhis D, Bourbonne V , et al. New automated method for lung functional volumes delineation with lung perfusion PET/CT imaging. *Cancers (Basel)* 2023;**15**:2166.

70. Lucia F, Hamya M, Pinot F, et al. A feasibility study of functional lung volume preservation during stereotactic body radiotherapy guided by Gallium-68 perfusion PET/CT. *Cancers* 2023;**15**:1726.

71. Wei Y, Sun Y, Liu J, et al. Early detection of radiation-induced myocardial damage by [18F]AlF-NOTA-FAPI-04 PET/CT imaging. *Eur J Nucl Med Mol Imaging* 2023;**50**:453-64.

72. Rectal Cancer, Version 1.2024, NCCN clinical practice guidelines in oncology. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461

73. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. *Int J Radiat Oncol Biol Phys* 2006;**65**:720-5.

74. Jones M, Hruby G, Solomon M, et al. The role of FDG-PET in the initial staging and response assessment of anal can-

cer: a systematic review and meta-analysis. *Ann Surg Oncol* 2015;**22**:3574-81.

75. Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. *Radiother Oncol* 2014;**113**:158-65.

76. Jadvar H. The VISION Forward: recognition and implication of PSMA-/18F-FDG+ mCRPC. *J Nucl Med* 2022;**63**:812-5.

77. Fendler WP, Calais J, Eiber M, , et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. *JAMA Oncol* 2019;**5**:856-63.

78. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR Phase III, multicenter study. *Clin Cancer Res* 2021;**27**:3674-82.

79. Zacho HD, Fonager RF, Nielsen JB, , et al. Observer Agreement and accuracy of 18F-Sodium fluoride PET/CT in the diagnosis of bone metastases in prostate cancer. *J Nucl Med* 2020;**61**:344-9.

80. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet* 2020;**395**:1208-16.

81. Salem AE, Fine GC, Covington MF, , et al. PET-CT in clinical adult oncology-IV. gynecologic and genitourinary malignancies. *Cancers (Basel)* 2022;**14**:3000.

82. Mottet N, van den Bergh RC, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2021;**79**:243-62.

83. Pernthaler B, Kulnik R, Gstettner C, et al. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nucl Med 2019;44:e566-73.

84. Liu F, Dong J, Shen Y, et al. Comparison of PET/CT and MRI in the diagnosis of bone metastasis in prostate cancer patients: a network analysis of diagnostic studies. *Front Oncol* 2021;**11**:736654.

85. Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. *Eur Urol* 2020;**77**:403-17.

86. Miksch J, Bottke D, Krohn T, et al. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. *Eur J Nucl Med Mol Imaging* 2020;**47**:2339-47.

87. Guberina N, Hetkamp P, Ruebben H, et al. Whole-body integrated [68Ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. *Mol Imaging Biol* 2020;**22**:788-96.

88. Eiber M, Rauscher I, Souvatzoglou M, , et al. Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:2179-88.

89. Schiller K, Stöhrer L, Düsberg M, et al. PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. *Eur Urol Oncol* 2021;**4**:73-83.

90. Slevin F, Beasley M, Cross W, et al. Patterns of lymph node failure in patients with recurrent prostate cancer postradical prostatectomy and implications for salvage therapies. *Adv Radiat Oncol* 2020;**5**:1126-40.

91. Valle L, Shabsovich D, de Meerleer G, et al. Use and impact of positron emission tomography/computed tomography prior to salvage radiation therapy in men with biochemical recurrence after radical prostatectomy: a scoping review. *Eur Urol Oncol* 2021;**4**:339-55.

92. Artigas C, Otte F-X, Lemort M, et al. Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA Ligand PET/CT. *Clin Nucl Med* 2017;**42**:368-70.

93. Reale ML, Buttigliero C, Tucci M, et al. 68Ga-PSMA Uptake in fibrous dysplasia. *Clin Nucl Med* 2019;**44**:e396-7.

94. Draulans C, Pos F, Smeenk RJ, et al. 68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for gross tumor volume delineation in primary prostate cancer: intermodality and intertracer variability. *Pract Radiat Oncol* 2021;**11**:202-11.

95. Chen M, Zhang Q, Zhang C, et al. Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. *Transl Androl Urol* 2020;**9**:382-90.

96. Bettermann AS, Zamboglou C, Kiefer S, et al. [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. *Radiother Oncol* 2019;**141**:214-9.

97. Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. *J Nucl Med* 2018;**59**:230-7.

98. Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. *BMC Cancer* 2019;**19**:18.

99. Kerkmeijer LG, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized PHASE III trial. *J Clin Oncol* 2021;**39**:787-96.

100. Zamboglou C, Schiller F, Fechter T, et al. (68)Ga-HBED-CC-PSMA PET/CT *versus* histopathology in primary localized prostate cancer: a voxel-wise comparison. *Theranostics* 2016;**6**:1619-28.

101. Bettermann AS, Zamboglou C, Kiefer S, et al. [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. *Radiother Oncol* 2019;**141**:214-9.

102. Kostyszyn D, Fechter T, Bartl N, et al. Intraprostatic Tumor segmentation on PSMA PET images in patients with primary prostate cancer with a convolutional neural network. *J Nucl Med* 2021;**62**:823-8.

103. Zamboglou C, Fassbender TF, Steffan L, et al. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. *Radiother Oncol* 2019;**141**:208-13.

104. Zamboglou C, Sachpazidis I, Koubar K, et al. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. *Radiother Oncol* 2017;**123**:472-7.

105. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;**372**:1598-607.

106. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. *N Engl J Med* 2016;**374**:2419-29.

107. Cheson BD, Fisher RI, Barrington SF, , et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014;**32**:3059-68.

108. Figura N, Flampouri S, Mendenhall NP, et al. Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. *Adv Radiat Oncol* 2017;**2**:197-203.

109. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). *Int J Radiat Oncol Biol Phys* 2014;**89**:854-62.

110. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. *Radiother Oncol* 2006;**79**:270-7.

111. Macpherson RE, Pratap S, Tyrrell H, et al. Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. *Clin Sarcoma Res* 2018;**8**:9.

112. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. *Br J Cancer* 2001;**84**:1070-5.

113. Kessler L, Ferdinandus J, Hirmas N, et al. 68Ga-FAPI as a Diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial. J Nucl Med 2022;63:89-95.

114. Adam JA, van Diepen PR, Mom CH, et al. [18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature. *Gynecol Oncol* 2020;**159**:588-96.

115. Leblanc E, Gauthier H, Querleu D, et al. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. *Ann Surg Oncol* 2011;**18**:2302-9.

116. De Cuypere M, Lovinfosse P, Goffin F, et al. Added value of para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. *Eur J Surg Oncol* 2020;**46**:883-7.

117. Lucia F, Bourbonne V, Pleyers C, et al. Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer. *Eur J Nucl Med Mol Imaging* 2023;**50**:2514-28.

118. Martinez A, Lecuru F, Bizzarri N, et al. PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study. *Int J Gynecol Cancer* 2023;**33**:293-8.

119. Gouy S, Seebacher V, Chargari C, et al. False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology. *BMC Cancer* 2021;**21**:135.

120. Gee MS, Atri M, Bandos AI, et all. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. *Radiology* 2018;**287**:176-84.

121. Ferreira M, Lovinfosse P, Hermesse J, et al. [18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation. *Eur J Nucl Med Mol Imaging* 2021;**48**:3432-43.

122. Han L, Wang Q, Zhao L , et al. A systematic review and meta-analysis of the prognostic impact of pretreatment fluorodeoxyglucose positron emission tomography/computed tomography parameters in patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy. *Diagnostics (Basel)* 2021;**11**:1258.

123. Lucia F, Visvikis D, Vallières M, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. *Eur J Nucl Med Mol Imaging* 2019;**46**:864-77.

124. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. *JAMA* 2007;**298**:2289-95.

125. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 2012;**83**:185-90.

126. Sertic M, Kilcoyne A, Catalano OA, Lee SI. Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT. *Abdom Radiol (NY)* 2022;**47**:3174-88.

127. Morsing A, Hildebrandt MG, Vilstrup MH, et al. Hybrid PET/MRI in major cancers: a scoping review. *Eur J Nucl Med Mol Imaging* 2019;**46**:2138-51.

128. Damian A, Lago G, Rossi S, et al. Early detection of bone metastasis in small cell neuroendocrine carcinoma of the cervix by 68Ga-DOTATATE PET/CT imaging. *Clin Nucl Med* 2017;**42**:216-7.

129. Ponisio MR, Dehdashti F. A role of PET agents beyond fdg in gynecology. *Semin Nucl Med* 2019;**49**:501-11.

130. Wyss JC, Carmona R, Karunamuni RA,et al. [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients. *Radiother Oncol* 2016;**118**:72-8.

131. Dendl K, Koerber SA, Finck R, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. *Eur J Nucl Med Mol Imaging* 2021;**48**:4089-100.

132. Nguyen NC, Vercher-Conejero JL, Sattar A, et al. Image quality and diagnostic performance of a digital PET prototype in patients with oncologic diseases: initial experience and comparison with analog PET. *J Nucl Med* 2015;**56**:1378-85.

133. Oderinde OM, Shirvani SM, Olcott PD, et al. The technical design and concept of a PET/CT linac for biology-guided radiotherapy. *Clin Transl Radiat Oncol* 2021;**29**:106-12.

134. Fassbender TF, Schiller F, Zamboglou C, et al. Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. *EJNMMI Res* 2020;**10**:62.

135. Lucia F, Miranda O, Abgral R, , et al. Use of baseline 18 F-FDG PET/CT to identify initial sub-volumes associated with local failure after concomitant chemoradiotherapy in locally advanced cervical cancer. *Front Oncol* 2020;**10**:678.

136. Vorwerk H, Zink K, Schiller R, , et al. Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT. *Strahlenther Onkol* 2014;**190**:433-43.

137. Njeh CF. Tumor delineation: the weakest link in the search for accuracy in radiotherapy. *J Med Phys* 2008;**33**:136-40.

138. Gardin I. Methods to delineate tumour for radiotherapy by fluorodeoxyglucose positron emission tomography. *Cancer Radiother* 2020;**24**:418-22.

139. Milletari F, Navab N, Ahmadi S-A. V-Net: fully convolutional neural networks for volumetric medical image segmentation. ArXiv 2016. Available from: https://arxiv.org/abs/1606.04797

140. Iantsen A, Ferreira M, Lucia F, et al. Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting. *Eur J Nucl Med Mol Imaging* 2021;**48**:3444-56.

141. Ronneberger O, Fischer P, Brox T. U-Net: convolutional networks for biomedical image segmentation. ArXiv 2015. Available from: https://arxiv.org/abs/1505.04597

142. Lian C, Ruan S, Denoeux T, et al. Joint tumor segmentation in PET-CT images using co-clustering and fusion based on belief functions. *IEEE Trans Image Process* 2019;**28**:755-66.

143. Zhao X, Li L, Lu W, Tan S. Tumor co-segmentation in PET/CT using multi-modality fully convolutional neural network. *Phys Med Biol* 2018;**64**:015011.

144. Thorwarth D, Beyer T, Boellaard R, et al. Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches. *Nuklearmedizin* 2012;**51**:140-53.

145. Cook GJR, Azad G, Owczarczyk K,et al Challenges and promises of PET radiomics. *Int J Radiat Oncol Biol Phys* 2018;**102**:1083-9.

Les demandes de tirés à part doivent être adressées au Pr Lucia F, Département de Radiothérapie-Oncologie, Hôpital Universitaire de Brest, France.

Email : francois.lucia@chu-brest.fr